News | February 04, 2025
Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
